Christy Jones Sells 1,406 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 1,406 shares of Beta Bionics stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $15.00, for a total value of $21,090.00. Following the completion of the sale, the director owned 25,994 shares in the company, valued at approximately $389,910. This represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, June 4th, Christy Jones sold 2,811 shares of Beta Bionics stock. The shares were sold at an average price of $14.00, for a total value of $39,354.00.
• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total value of $19,880.10.

Beta Bionics Stock Up 5.7%

NASDAQ:BBNX opened at $16.82 on Friday. The stock has a market cap of $749.53 million, a P/E ratio of -11.14 and a beta of 3.40. The firm’s fifty day simple moving average is $12.13 and its 200 day simple moving average is $15.58. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million during the quarter. On average, analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current fiscal year.

Institutional Trading of Beta Bionics

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of Beta Bionics by 3,238.0% during the third quarter. JPMorgan Chase & Co. now owns 205,955 shares of the company’s stock valued at $4,092,000 after purchasing an additional 199,785 shares in the last quarter. Pura Vida Investments LLC boosted its position in shares of Beta Bionics by 11,150.0% during the third quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock valued at $5,588,000 after buying an additional 278,750 shares during the last quarter. SG Americas Securities LLC bought a new stake in Beta Bionics in the 4th quarter worth about $4,579,000. Farallon Capital Management LLC increased its holdings in Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after buying an additional 110,000 shares in the last quarter. Finally, First Eagle Investment Management LLC purchased a new position in Beta Bionics in the 3rd quarter worth about $4,634,000.

Wall Street Analyst Weigh In

Several analysts have commented on BBNX shares. Bank of America lowered their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. The Goldman Sachs Group reduced their target price on Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Leerink Partners decreased their target price on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Stifel Nicolaus dropped their price target on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Finally, Truist Financial reduced their price target on Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and an average target price of $19.70.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.